Physician profile
Jillian E Parsons
NPI 1043730229
$474.80
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.50 · 2022: $172 · 2023: $217 · 2024: $47.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $264.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $104.49 | 2023 | Myrisk |
| Amgen INC. | $68.12 | 2021-2023 | Evenity, Prolia |
| Abbvie INC. | $43.78 | 2021-2024 | |
| Novo Nordisk INC | $40.88 | 2022-2023 | Rybelsus, Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $30.44 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $29.61 | 2022 | |
| Teleflex LLC | $17.31 | 2022 | |
| Merck Sharp & Dohme LLC | $16.38 | 2023 | Proquad, Vaxelis, Vaxneuvance |
| Lundbeck LLC | $15.51 | 2023 | Rexulti |
| Boston Scientific Corporation | $15.11 | 2024 | |
| Astellas Pharma US INC | $14.36 | 2024 | Veozah |
| Lilly USA, LLC | $14.27 | 2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.26 | 2023 | Xifaxan |
| Insulet Corporation | $13.13 | 2022 | |
| Pfizer INC. | $13.04 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12.83 | 2023 | Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $12.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Parsons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.